Ra Capital Management, L.P. - Feb 17, 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Director
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
CTKB
Transactions as of
Feb 17, 2022
Transactions value $
$7,695,707
Form type
4
Date filed
2/22/2022, 04:22 PM
Previous filing
Apr 28, 2022
Next filing
Feb 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Purchase $2.46M +166K +1.64% $14.78 10.3M Feb 17, 2022 See footnotes F1, F2, F3, F8
transaction CTKB Common Stock Purchase $2.35M +166K +1.62% $14.12 10.4M Feb 18, 2022 See footnotes F1, F4, F5, F8
transaction CTKB Common Stock Purchase $2.89M +215K +2.06% $13.46 10.7M Feb 22, 2022 See footnotes F1, F6, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established December 14, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $14.50 to $15.39; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 These securities include 8,578,395 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund"), 1,185,767 shares held by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and 507,724 shares held by a separately managed account (the "Account").
F4 This transaction was executed in multiple trades at prices ranging from $13.63 to $14.79; the price reported above reflects the weighted average purchase price.
F5 These securities include 8,744,624 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
F6 This transaction was executed in multiple trades at prices ranging from $12.89 to $13.76; the price reported above reflects the weighted average purchase price.
F7 These securities include 8,959,546 shares held directly by the Fund, 1,185,767 shares held by Nexus Fund II, and 507,724 shares held by the Account.
F8 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Theresa Cameron, a Principal of the Adviser, serves on the Issuer's board of directors.